Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ACADEMIA
Nephrology Society Compiles New Drug Development Guidelines for Advanced CKD; Will Guidelines for Early-Stage CKD Follow?
The Japanese Society of Nephrology (JSN) has finalized guidelines designed to spur the development of new drugs for kidney disease. The guidelines aim to reduce the time, number of patients, and cost required for clinical trials through the use of…
To read the full story
Related Article
- Nephrology Society Poised to Compile Drug Development Guidelines for Early-Stage Kidney Disease
October 18, 2019
- Japanese Society of Nephrology Wins AMED Funding for “Surrogate Endpoint” Guidelines
August 8, 2016
- Japanese Society of Nephrology Aims to Promote Development through “Surrogate Endpoints”; Hopes to Draft Guidelines in FY2017
July 22, 2016
ACADEMIA
- Urine-Derived Stem Cells Eyed as New Drug Discovery Tool
June 10, 2026
- Japan Cancer Center Lowers Recommended BMI Ceiling for Men to 25
June 5, 2026
- Tavneos Data Integrity Issue Could Spill Over to Japan, Investigator Warns
June 2, 2026
- Arava Safety Backup at Risk as Questran Supply Falters on Nitrosamine Issue
May 11, 2026
- NCC Launches First Japan Trial for CP Inhibitor-Related Liver Dysfunction
April 27, 2026
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…